5 Neuro Data Readouts to Watch in the Second Half of 2024 7/15/2024
SignalChem Biotech, World Leader in Kinases, Is Now Part of Sino Biological 7/15/2024
Opinion: Congress Must Reauthorize FDA Program for Pediatric Rare Diseases 7/15/2024
Boehringer, Zealand Heat Up MASH Race With Strong Phase II Data 6/7/2024
FDA Raises Concerns About Lilly’s Donanemab Alzheimer’s Candidate Ahead of Adcomm 6/7/2024
FDA Approves Geron’s First-in-Class Telomerase Inhibitor for Blood Disorder 6/7/2024
Biomea’s Stock Nosedives More Than 60% as FDA Puts Clinical Hold on Diabetes Candidate 6/7/2024
MASH Clash Between Lilly and Boehringer-Zealand Takes Center Stage at EASL24 6/7/2024
AbbVie Sees Early ROI on $10B Immunogen Buy in Phase II Ovarian Cancer Win 6/7/2024
Vanda Gets $466M Unsolicited Offer from Cycle Amid Ongoing Row with FDA 6/7/2024
Flagship-Backed Prologue Launches with $50M to DELVE into Viral Proteome 5/7/2024
Vertex Touts 13% Revenue Jump, Beats Profit Estimates on Strong Cystic Fibrosis Performance 5/7/2024
AAV Manufacturing Takes Center Stage at ASGCT24 5/7/2024
ADC Therapeutics Posts Early Phase II Lymphoma Data for Zynlonta as Revenue Drops 5.8% 5/7/2024
Preliminary Findings Point to Low Risk of Secondary Cancers from CAR-T Therapies 5/7/2024
FDA Sets Date for Eli Lilly’s Donanemab Adcomm While Pondering Changes to Format 5/7/2024
FDA Rejects Rocket’s Gene Therapy, Cites Need for Additional CMC Info 6/28/2024
Alumis Pushes Through With Smaller IPO, Looks to Raise $250M for Immuno Candidate 6/28/2024
ICER Doubles Down on Critique of Lykos’ MDMA Therapy, Cites Data Concerns 6/28/2024
FDA Needs to Step Up As Use of Third-Party Manufacturers Leads to Rejections 6/28/2024